CM Life Sciences, Inc. (CMLF) Completes Sema4 Deal
by Marlena Haddad on 2021-07-22 at 7:16am

CM Life Sciences, Inc.  (NASDAQ:CMLF) announced this morning that its shareholders approved its combination with genomic and clinical data intelligence company Sema4 and the transaction has now been completed.

The release and an earlier 8-K filing did not disclose redemption figures, but CM Life Sciences traded above $11 through the day of its July 19 redemption deadline and so it is unlikely shareholders redeemed in large numbers, if any. The press release also noted that Sema4 expected to receive $500 million in total proceeds as a part of the deal, which was the amount the parties expected to add to the company’s balance sheet at announcement.

The combined company is now slated to begin trading its shares and warrants on the Nasdaq under the ticker symbols “SMFR” and “SMFRW” beginning Friday, July 23.

The parties initially inked the $2.1 billion deal on February 10. Sema4 is dedicated to transforming healthcare by building dynamic models of human health and defining optimal, individualized health trajectories, starting in the areas of reproductive health and oncology.

Sema4 announced earlier this month that its post-transaction Board would be joined by Jason Ryan, former CFO at Magenta Therapeutics (NASDAQ:MGTA) and Foundation Medicine. CM Life Sciences has maintained strong momentum through the down market and never traded below trust value through the slump.

All measures on CM Life Science’s ballot passed by wide margins but some received as many as 17% votes against. For a full list of proposals and vote tallies, click HERE.


ADVISORS

  • Jefferies LLC is acting as sole financial advisor, lead capital markets advisor, and sole placement agent to CM Life Sciences
  • Cowen and Company, LLC is also acting as a capital markets advisor to CM Life Sciences
  • White & Case LLP is serving as legal advisor to CM Life Sciences
  • Goldman Sachs & Co. LLC and J.P. Morgan Securities LLC are serving as financial advisors to Sema4
  • Fenwick & West LLP is serving as legal advisor to Sema4
Recent Posts
by Nicholas Alan Clayton on 2024-03-28 at 7:47am

At the SPAC of Dawn Fed Chair Jerome Powell has given new hints that the administration would be showing greater levels of comfort with inflation if a cut could help improve unemployment numbers. Those numbers could get an update today at 8:30 am ET to bring new jobless claims as well as final prices for...

by Nicholas Alan Clayton on 2024-03-27 at 1:31pm

News and Rumors CNBC: Former WeWork (OTC Pink:WEWKQ) founder Adam Neumann has offered to buy back control of the company for $500 million but has yet to secure the necessary financing. WeWork went public with BowX in October 2021. PR: Satellite telecom firm Spire Global (NYSE:SPIR) has signed an agreement to build and launch two...

by Nicholas Alan Clayton on 2024-03-27 at 11:38am

Bannix (NASDAQ:BNIX) has entered into a definitive agreement to combine with VisionWave Technologies for $30 million. The combined company is expected to trade on the Nasdaq once the deal is completed with an initial outside date of September 14. Transaction Overview Bannix has about $17 million in its trust after seeing 77.4% of its shares...

by Nicholas Alan Clayton on 2024-03-27 at 7:33am

At the SPAC of Dawn Much of the attention yesterday was on tracking the swings of the newly-completed Trump Media (NASDAQ:DJT) deal with the FT going as far to suggest it may “make SPACs great again.” Not all of the day’s data points were on the positive side of the ledger, however. IB Acquisition Corp....

by Nicholas Alan Clayton on 2024-03-26 at 1:52pm

News and Rumors SpaceNews: Boeing (NYSE:BA) has sued Virgin Galactic (NASDAQ:SPCE) alleging the space tourism venture refused to pay $25 million it owed for design work and violated Boeing’s intellectual property rights. Virgin Galactic combined with Social Capital Hedosophia in 2019. Bloomberg: The most popular options contract for Trump Media (NASDAQ:DJT) predicts it to plunge...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved